IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

CHANGE OF CONTINUING SPONSOR

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**" together with its subsidiaries, the "**Group**") wishes to announce that the Company has appointed UOB Kay Hian Private Limited ("**UOBKH**") to act as its new continuing sponsor with effect from 1 June 2021 in place of the current continuing sponsor, CIMB Bank Berhad, Singapore Branch ("**CIMB**"). The change of continuing sponsor is due to commercial reasons relating to CIMB.

Pursuant to Rule 228(5) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**"), CIMB, as the current continuing sponsor of the Company, has confirmed that as at the date of this announcement and based on information made available to CIMB, it is not aware of any non-compliance with the Catalist Rules by the Company that has not been brought to the attention of UOBKH. CIMB has also made itself available for discussion with UOBKH as required under Rule 228(3) of the Catalist Rules.

The Board would like to take this opportunity to express its appreciation to CIMB for its past guidance and sponsorship.

By Order of the Board

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

31 May 2021

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.